Local children may be able to get the COVID-19 vaccine early by participating in a vaccine trial of the Moderna vaccine through UPMC Children’s Hospital of Pittsburgh.

The hospital, through the Pittsburgh Vaccine Trials Unit, announced Wednesday that they are now enrolling children ages 6 months to 12 years old in the “KidCOVE” Moderna vaccine trial.

“Last year, Pittsburghers rolled up their sleeves and volunteered to participate in our local Moderna vaccine adult trials, helping to make this vaccine available to the public in record time,” said Dr. Judy Martin, professor of pediatrics at the University of Pittsburgh School of Medicine and member of the University of Pittsburgh’s Center for Vaccine Research. “We are excited to now have the opportunity to invite our children to volunteer as well.”

For families that are interested, researchers at Pitt will be making phone calls and answering questions if their children might be selected to receive the vaccine. “It’s really just going to be an individual decision for the families that are interested,” said Dr. Martin. “We’ll engage in conversation with them to let them know the details and the risks and benefits to make a decision. We anticipate having these conversations and answering lots of questions.”

Advertise with us

The testing will go in phases -- first children between 6 and 12 years old, then 2 to 6 years old and then 6 months to 2 years old. Dr. Martin anticipates that the first shots may be available for the oldest of those age groups in late July or early August. Pittsburgh is one of 100 sites across the United States and Canada participating in the Moderna trial, which aims to enroll 7,050 children.

Pittsburgh is not one of the sites testing the Pfizer vaccine for children, so this is the first opportunity for local children under 12 to be vaccinated, said Dr. Martin. “We know there’s a lot of interest from families in helping science and getting potential vaccine for their kids.”

Pittsburgh children will participate in both Phase 2 and Phase 3 of the Moderna trial (Phase 1 is considered to be already completed as part of the adult study). Phase 2 will test dosage levels, with children between 3 and 12 years old getting either a 50 microgram dose or 100 microgram dose and children 6 months to age 2 getting either 25 micrograms, 50 micrograms or 100 micrograms. Adults currently receive 100 micrograms of Moderna and like adults, all children in the study will receive a booster dose 28 days later.

During Phase 2, scientists will monitor side effects to assess the safety of the vaccine in children and will also measure antibody response to see how well the vaccine is working. “They start with lower doses and work up,” said Dr. Martin, “trying to find the balance of limiting side effects but getting the correct antibody response.”

One the ideal dose for an age group is determined, the trial will move on to Phase 3 for that age group, which recruits a new group of children to test how well the vaccine works at preventing or limiting COVID in comparison to a placebo. Out of every four participants in Phase 3, three will get the vaccine and one will get a placebo. Neither the children, their parents or their pediatricians will know during the trial whether they received the vaccine or a placebo. Those who got a placebo will be given first dibs on the vaccine when it is approved for children.

Advertise with us

The children will be followed for a year to determine the vaccine’s effectiveness.

During the vaccine trials for adults, researchers determined effectiveness by tracking how many people who were vaccinated tested positive for COVID-19 versus those who received a placebo. Given that COVID-19 case counts have fallen so dramatically in recent months, it will be up to the U.S. Food and Drug Administration to determine what standard it will use to determine effectiveness of the vaccine in children, said Dr. Martin.

Registration for the trial is open at PVTU.org and more information is available at www.kidcovestudy.com.

Anya Sostek: asostek@post-gazette.com.